Overview

Optimizing the Use of Ketamine to Reduce Chronic Postsurgical Pain

Status:
Not yet recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
Our study utilizes a 3-arm placebo-controlled RCT to study the effectiveness of ketamine in reducing chronic post-mastectomy pain. Participants randomized to the first arm will receive a 0.35 mg/kg dose after induction, followed by a 0.3 mg/kg/hr infusion throughout surgery and continued for 2 hours postoperatively. Participants in the second arm will receive a single dose of 0.6 mg/kg of ketamine in the post-anesthesia care unit, and the final group will serve as the control group and receive saline (no ketamine).
Phase:
Phase 3
Details
Lead Sponsor:
NYU Langone Health
Collaborator:
National Cancer Institute (NCI)
Treatments:
Ketamine